Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
LMNX's Cash to Debt is ranked higher than
98% of the 200 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.70 vs. LMNX: No Debt )
Ranked among companies with meaningful Cash to Debt only.
LMNX' s Cash to Debt Range Over the Past 10 Years
Min: 3.96  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.93
LMNX's Equity to Asset is ranked higher than
97% of the 195 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.62 vs. LMNX: 0.93 )
Ranked among companies with meaningful Equity to Asset only.
LMNX' s Equity to Asset Range Over the Past 10 Years
Min: 0.77  Med: 0.89 Max: 0.97
Current: 0.93
0.77
0.97
Interest Coverage No Debt
LMNX's Interest Coverage is ranked higher than
98% of the 123 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 18.08 vs. LMNX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
LMNX' s Interest Coverage Range Over the Past 10 Years
Min: 5.66  Med: 77.41 Max: 9999.99
Current: No Debt
5.66
9999.99
F-Score: 6
Z-Score: 22.92
M-Score: -2.42
WACC vs ROIC
2.32%
18.17%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 16.24
LMNX's Operating margin (%) is ranked higher than
80% of the 196 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.10 vs. LMNX: 16.24 )
Ranked among companies with meaningful Operating margin (%) only.
LMNX' s Operating margin (%) Range Over the Past 10 Years
Min: -23.22  Med: 7.04 Max: 15.72
Current: 16.24
-23.22
15.72
Net-margin (%) 15.71
LMNX's Net-margin (%) is ranked higher than
86% of the 196 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.00 vs. LMNX: 15.71 )
Ranked among companies with meaningful Net-margin (%) only.
LMNX' s Net-margin (%) Range Over the Past 10 Years
Min: -3.61  Med: 4.91 Max: 17.2
Current: 15.71
-3.61
17.2
ROE (%) 10.92
LMNX's ROE (%) is ranked higher than
69% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.62 vs. LMNX: 10.92 )
Ranked among companies with meaningful ROE (%) only.
LMNX' s ROE (%) Range Over the Past 10 Years
Min: -3.44  Med: 3.96 Max: 13.24
Current: 10.92
-3.44
13.24
ROA (%) 9.99
LMNX's ROA (%) is ranked higher than
83% of the 201 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.92 vs. LMNX: 9.99 )
Ranked among companies with meaningful ROA (%) only.
LMNX' s ROA (%) Range Over the Past 10 Years
Min: -2.85  Med: 3.35 Max: 11.77
Current: 9.99
-2.85
11.77
ROC (Joel Greenblatt) (%) 41.41
LMNX's ROC (Joel Greenblatt) (%) is ranked higher than
81% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.41 vs. LMNX: 41.41 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
LMNX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -12.68  Med: 22.71 Max: 40.65
Current: 41.41
-12.68
40.65
Revenue Growth (3Y)(%) 4.80
LMNX's Revenue Growth (3Y)(%) is ranked higher than
51% of the 158 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. LMNX: 4.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
LMNX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 4.8  Med: 18.60 Max: 194.3
Current: 4.8
4.8
194.3
EBITDA Growth (3Y)(%) 10.40
LMNX's EBITDA Growth (3Y)(%) is ranked higher than
57% of the 137 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.30 vs. LMNX: 10.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
LMNX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -66.9  Med: 9.20 Max: 45.3
Current: 10.4
-66.9
45.3
EPS Growth (3Y)(%) 42.10
LMNX's EPS Growth (3Y)(%) is ranked higher than
85% of the 130 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.60 vs. LMNX: 42.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
LMNX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -53.4  Med: 2.55 Max: 104.9
Current: 42.1
-53.4
104.9
» LMNX's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-03)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

LMNX Guru Trades in Q2 2015

Chuck Royce 3,200 sh (New)
Jim Simons 537,715 sh (+75.78%)
Paul Tudor Jones 52,189 sh (+6.08%)
» More
Q3 2015

LMNX Guru Trades in Q3 2015

Joel Greenblatt 171,460 sh (New)
Chuck Royce 5,900 sh (+84.38%)
Jim Simons 751,203 sh (+39.70%)
Paul Tudor Jones 37,097 sh (-28.92%)
» More
Q4 2015

LMNX Guru Trades in Q4 2015

Joel Greenblatt 209,221 sh (+22.02%)
Paul Tudor Jones 43,487 sh (+17.23%)
Jim Simons 846,040 sh (+12.62%)
Chuck Royce Sold Out
» More
Q1 2016

LMNX Guru Trades in Q1 2016

Jim Simons 1,007,840 sh (+19.12%)
Paul Tudor Jones 36,086 sh (-17.02%)
Joel Greenblatt 62,983 sh (-69.90%)
» More
» Details

Insider Trades

Latest Guru Trades with LMNX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:NAS:ATRI, OTCPK:TOPCF, NAS:MMSI, NYSE:GKOS, NAS:ELGX, NAS:NVCR, NAS:ANGO, OTCPK:NNCSF, NAS:ATRC, NAS:NXTM, NAS:MLAB, NAS:OSUR, NAS:ENTL, NAS:LMAT, NYSE:HAE, NAS:CFMS, AMEX:CRHM, NAS:STAA, NAS:UTMD, NYSE:HYH » details
Traded in other countries:LMX.Germany,
Luminex Corp develops, manufactures and sells proprietary biological testing technologies and products with applications throughout the life sciences and diagnostics industries. Its products include MAGPIX, Luminex 100/200, & FLEXMAP 3D.

Luminex Corp was incorporated under the laws of the State of Texas in May 1995, and was reincorporated in the State of Delaware in July 2000. The Company develops, manufactures and sells proprietary biological testing technologies and products with applications throughout the life sciences and diagnostics industries. The Company has two reportable segments; TSP segment and ARP segment. The TSP segment represents the Company's base business and consists of system sales to partners, raw bead sales, royalties, service and support of the technology, and other miscellaneous items and the ARP segment is involved in the development and sale of assays on xMAP technology for use on Luminex's installed base of systems, as well as the sale of automated punching systems. The Company also develops and manufactures the proprietary xMAP laboratory instrumentation and the proprietary xMAP microspheres and sells them. The ARP segment is mainly involved in the development and sale of assays utilizing xMAP technology on its installed base of systems. The ARP segment is mainly focused on multiplexed applications for the human molecular clinical diagnostics market. The Company's diagnostic market competitors include Abbott Laboratories, Beckman Coulter, Inc., Celera Corporation, Cepheid, Johnson & Johnson, Roche Diagnostics, Siemens Medical, and Hologic, Inc. It currently owns 281 issued patents, including 110 issued patents in the United States. The Company's trademark includes Luminex, xMAP, xTAG, Luminex 100/200 MicroPlex, MAGPIX, MagPlex, SeroMAP, xPONENT, FlexmiR, NeoPlex4, LumAvidin Et cetera. The Company is subject to federal, state and local laws and regulations relating to the protection of human health and the environment.

Ratios

vs
industry
vs
history
P/E(ttm) 24.06
LMNX's P/E(ttm) is ranked higher than
60% of the 121 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 28.89 vs. LMNX: 24.06 )
Ranked among companies with meaningful P/E(ttm) only.
LMNX' s P/E(ttm) Range Over the Past 10 Years
Min: 16.42  Med: 63.86 Max: 603.33
Current: 24.06
16.42
603.33
PE(NRI) 24.06
LMNX's PE(NRI) is ranked higher than
60% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 28.89 vs. LMNX: 24.06 )
Ranked among companies with meaningful PE(NRI) only.
LMNX' s PE(NRI) Range Over the Past 10 Years
Min: 16.42  Med: 63.86 Max: 603.33
Current: 24.06
16.42
603.33
Price/Owner Earnings (ttm) 34.56
LMNX's Price/Owner Earnings (ttm) is ranked lower than
61% of the 76 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 28.98 vs. LMNX: 34.56 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
LMNX' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 21.7  Med: 59.39 Max: 903.5
Current: 34.56
21.7
903.5
P/B 2.43
LMNX's P/B is ranked higher than
57% of the 207 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.89 vs. LMNX: 2.43 )
Ranked among companies with meaningful P/B only.
LMNX' s P/B Range Over the Past 10 Years
Min: 2.02  Med: 3.32 Max: 12.31
Current: 2.43
2.02
12.31
P/S 3.76
LMNX's P/S is ranked lower than
59% of the 212 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.03 vs. LMNX: 3.76 )
Ranked among companies with meaningful P/S only.
LMNX' s P/S Range Over the Past 10 Years
Min: 2.87  Med: 5.17 Max: 12.94
Current: 3.76
2.87
12.94
PFCF 22.95
LMNX's PFCF is ranked higher than
58% of the 84 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 26.29 vs. LMNX: 22.95 )
Ranked among companies with meaningful PFCF only.
LMNX' s PFCF Range Over the Past 10 Years
Min: 19.41  Med: 58.83 Max: 440.73
Current: 22.95
19.41
440.73
POCF 17.13
LMNX's POCF is ranked lower than
57% of the 103 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 15.88 vs. LMNX: 17.13 )
Ranked among companies with meaningful POCF only.
LMNX' s POCF Range Over the Past 10 Years
Min: 12.22  Med: 31.33 Max: 270
Current: 17.13
12.22
270
EV-to-EBIT 20.14
LMNX's EV-to-EBIT is ranked higher than
50% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 20.84 vs. LMNX: 20.14 )
Ranked among companies with meaningful EV-to-EBIT only.
LMNX' s EV-to-EBIT Range Over the Past 10 Years
Min: -999.3  Med: 32.20 Max: 632.6
Current: 20.14
-999.3
632.6
EV-to-EBITDA 14.56
LMNX's EV-to-EBITDA is ranked higher than
57% of the 134 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.39 vs. LMNX: 14.56 )
Ranked among companies with meaningful EV-to-EBITDA only.
LMNX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -105217.5  Med: 25.00 Max: 4060.3
Current: 14.56
-105217.5
4060.3
PEG 1.72
LMNX's PEG is ranked higher than
72% of the 61 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.59 vs. LMNX: 1.72 )
Ranked among companies with meaningful PEG only.
LMNX' s PEG Range Over the Past 10 Years
Min: 1.02  Med: 2.23 Max: 6.34
Current: 1.72
1.02
6.34
Shiller P/E 57.58
LMNX's Shiller P/E is ranked lower than
79% of the 48 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 40.46 vs. LMNX: 57.58 )
Ranked among companies with meaningful Shiller P/E only.
LMNX' s Shiller P/E Range Over the Past 10 Years
Min: 50.23  Med: 112.38 Max: 1224.5
Current: 57.58
50.23
1224.5
Current Ratio 10.73
LMNX's Current Ratio is ranked higher than
96% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.51 vs. LMNX: 10.73 )
Ranked among companies with meaningful Current Ratio only.
LMNX' s Current Ratio Range Over the Past 10 Years
Min: 2.39  Med: 8.21 Max: 59.71
Current: 10.73
2.39
59.71
Quick Ratio 9.19
LMNX's Quick Ratio is ranked higher than
96% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.69 vs. LMNX: 9.19 )
Ranked among companies with meaningful Quick Ratio only.
LMNX' s Quick Ratio Range Over the Past 10 Years
Min: 1.86  Med: 7.15 Max: 58.8
Current: 9.19
1.86
58.8
Days Inventory 165.67
LMNX's Days Inventory is ranked lower than
70% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 126.38 vs. LMNX: 165.67 )
Ranked among companies with meaningful Days Inventory only.
LMNX' s Days Inventory Range Over the Past 10 Years
Min: 69.92  Med: 155.77 Max: 182.42
Current: 165.67
69.92
182.42
Days Sales Outstanding 44.18
LMNX's Days Sales Outstanding is ranked higher than
78% of the 165 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.94 vs. LMNX: 44.18 )
Ranked among companies with meaningful Days Sales Outstanding only.
LMNX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.52  Med: 53.46 Max: 66.89
Current: 44.18
38.52
66.89
Days Payable 35.95
LMNX's Days Payable is ranked lower than
69% of the 163 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 53.12 vs. LMNX: 35.95 )
Ranked among companies with meaningful Days Payable only.
LMNX' s Days Payable Range Over the Past 10 Years
Min: 36.85  Med: 56.62 Max: 78.2
Current: 35.95
36.85
78.2

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.49
LMNX's Price/Net Cash is ranked higher than
62% of the 63 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 13.33 vs. LMNX: 7.49 )
Ranked among companies with meaningful Price/Net Cash only.
LMNX' s Price/Net Cash Range Over the Past 10 Years
Min: 3.74  Med: 10.53 Max: 135.19
Current: 7.49
3.74
135.19
Price/Net Current Asset Value 4.77
LMNX's Price/Net Current Asset Value is ranked higher than
60% of the 139 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.62 vs. LMNX: 4.77 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
LMNX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.85  Med: 7.08 Max: 40.76
Current: 4.77
2.85
40.76
Price/Tangible Book 3.29
LMNX's Price/Tangible Book is ranked higher than
56% of the 176 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.52 vs. LMNX: 3.29 )
Ranked among companies with meaningful Price/Tangible Book only.
LMNX' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.66  Med: 5.44 Max: 16.96
Current: 3.29
2.66
16.96
Price/Projected FCF 1.49
LMNX's Price/Projected FCF is ranked higher than
66% of the 93 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.91 vs. LMNX: 1.49 )
Ranked among companies with meaningful Price/Projected FCF only.
LMNX' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.3  Med: 2.89 Max: 11.2
Current: 1.49
1.3
11.2
Price/Median PS Value 0.72
LMNX's Price/Median PS Value is ranked higher than
80% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.15 vs. LMNX: 0.72 )
Ranked among companies with meaningful Price/Median PS Value only.
LMNX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.57  Med: 1.39 Max: 51.4
Current: 0.72
0.57
51.4
Price/Peter Lynch Fair Value 2.52
LMNX's Price/Peter Lynch Fair Value is ranked lower than
60% of the 42 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.52 vs. LMNX: 2.52 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
LMNX' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 1.24  Med: 3.13 Max: 25.89
Current: 2.52
1.24
25.89
Price/Graham Number 1.88
LMNX's Price/Graham Number is ranked higher than
62% of the 92 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.42 vs. LMNX: 1.88 )
Ranked among companies with meaningful Price/Graham Number only.
LMNX' s Price/Graham Number Range Over the Past 10 Years
Min: 1.5  Med: 4.19 Max: 16.53
Current: 1.88
1.5
16.53
Earnings Yield (Greenblatt) (%) 4.96
LMNX's Earnings Yield (Greenblatt) (%) is ranked higher than
73% of the 217 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.33 vs. LMNX: 4.96 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
LMNX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.2  Med: 2.40 Max: 6
Current: 4.96
0.2
6
Forward Rate of Return (Yacktman) (%) 12.04
LMNX's Forward Rate of Return (Yacktman) (%) is ranked higher than
65% of the 89 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.73 vs. LMNX: 12.04 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
LMNX' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -53.6  Med: 0.70 Max: 29.1
Current: 12.04
-53.6
29.1

More Statistics

Revenue (TTM) (Mil) $242.9
EPS (TTM) $ 0.89
Beta0.10
Short Percentage of Float13.38%
52-Week Range $16.16 - 23.75
Shares Outstanding (Mil)43.34

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Dec16
Revenue (Mil $)
EPS ($) 0.61
EPS w/o NRI ($) 0.61
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for LMNX

Headlines

Articles On GuruFocus.com
BSX and ABMD Highlight Increased Insider Buying in the Medical Technology Sector May 14 2013 
Luminex Corp. (LMNX) CEO Patrick J Balthrop buys 7,000 Shares Mar 02 2010 
Luminex Corp. (LMNX) CEO Patrick J Balthrop buys 7,000 Shares Nov 16 2009 

More From Other Websites
Edited Transcript of LMNX earnings conference call or presentation 29-Jul-16 12:30pm GMT Jul 29 2016
LUMINEX CORP Files SEC form 10-Q, Quarterly Report Jul 29 2016
Luminex Corp Earnings Call scheduled for 8:30 am ET today Jul 29 2016
Luminex posts 2Q profit Jul 28 2016
Luminex posts 2Q profit Jul 28 2016
LUMINEX CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Jul 28 2016
Luminex Corporation Second Quarter Earnings Release Scheduled for July 28; Revision to Conference... Jul 28 2016
4:12 pm Luminex beats by $0.15, beats on revs; guides Q3 revs above consensus; guides FY16 revs... Jul 28 2016
Luminex Corporation Reports Second Quarter 2016 Results Jul 28 2016
Q2 2016 Luminex Corp Earnings Release - After Market Close Jul 28 2016
Luminex Corporation Second Quarter Earnings Release Scheduled for July 28; Revision to Conference... Jul 20 2016
Luminex Corporation Receives FDA Clearance and CE-IVD Mark for the ARIES M1 System Jul 08 2016
Luminex Corporation Second Quarter Earnings Release Scheduled for July 28, 2016 Jul 08 2016
Luminex (LMNX) Rallies on FDA Nod for Aries M1 System Jul 07 2016
Luminex Gets FDA Approval And CE-IVD Mark For Its ARIES M1 System Jul 06 2016
Luminex Corporation Completes Acquisition of Nanosphere, Inc. Jul 06 2016
Luminex Corporation Receives FDA Clearance and CE-IVD Mark for the ARIES M1 System Jul 06 2016
Luminex Corporation Completes Acquisition of Nanosphere, Inc. Jul 05 2016
Luminex Closes Nanosphere Buyout, Maintains FY16 View Jul 04 2016
Luminex Corp. breached its 50 day moving average in a Bullish Manner : LMNX-US : July 1, 2016 Jul 01 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)